Simple jQuery Dropdowns

Browsing by Author John B. Porter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 16 of 16
Issue DateTitleAuthor(s)
1-Jan-2014Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasiroxAli T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Raffaella Origa; Zeynep Karakas; Dany Habr; Zewen Zhu; M. Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Ospedale Regional Microcitemie; Istanbul Tip Fakultesi; Novartis Pharmaceuticals; Universita degli Studi di Milano
12-Aug-2014Calibration of myocardial T2 and T1 against iron concentrationJohn Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J. Anderson; Sofia V. De Noronha; A. John Baksi; Mary N. Sheppard; John B. Porter; J. Malcolm Walker; John C. Wood; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Mike House; Greg Black; David N. Firmin; Timothy G. St. Pierre; Dudley J. Pennell; Royal Brompton Hospital; National Heart and Lung Institute; St George's Healthcare NHS Trust; UCL; Children's Hospital Los Angeles; E.O. Ospedali Galliera; Azienda Ospedaliera Brotzu; Mahidol University; University of Western Australia
1-Nov-2016Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assayMaciej W. Garbowski; Yongmin Ma; Suthat Fucharoen; Somdet Srichairatanakool; Robert Hider; John B. Porter; UCL; King's College London; Zhejiang Chinese Medical University; The Institute of Science and Technology for Research and Development, Mahidol University; Faculty of Medicine, Chiang Mai University
1-Jan-2011Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadDudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege University Medical School; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut
1-Jun-2013Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Yiyun Zhang; M. Domenica Cappellini; American University of Beirut Medical Center; UCL Cancer Institute; Mahidol University; University of Athens; Chulalongkorn University; Ospedale Regional Microcitemie; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano
1-Nov-2013Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T. Taher; John B. Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Renzo Galanello; Zeynep Karakas; Tomasz Lawniczek; Dany Habr; Jacqueline Ros; Zewen Zhu; M. Domenica Cappellini; American University of Beirut; UCL; Mahidol University; University of Athens; Chulalongkorn University; Universita degli Studi di Cagliari; Istanbul Tip Fakultesi; Novartis International AG; Novartis Pharmaceuticals; Universita degli Studi di Milano
1-Jun-2012Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia majorDudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen S. Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher; Royal Brompton Hospital; UCL; Universita degli Studi di Milano; University of Malaya Medical Centre; Cairo University; Ege Universitesi; Kuala Lumpur Hospital; Prince of Wales Hospital Hong Kong; Mahidol University; Ain Shams University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; American University of Beirut
18-Jun-2015Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok; Antonis Kattamis; M. Domenica Cappellini; Amal El-Beshlawy; Raffaella Origa; Mohsen Elalfy; Yurdanur Kilinç; Silverio Perrotta; Zeynep Karakas; Vip Viprakasit; Dany Habr; Niculae Constantinovici; Junwu Shen; John B. Porter; Ege University Medical School; University of Athens; Universita degli Studi di Milano; Cairo University; Universita degli Studi di Cagliari; Ain Shams University; Cukurova Universitesi; Child and of General and Specialist Surgery; Istanbul Tip Fakultesi; Mahidol University; Novartis Pharmaceuticals; Novartis International AG; UCL Cancer Institute
18-Jan-2013Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasVip Viprakasit; Norbert Gattermann; Jong Wook Lee; John B. Porter; Ali T. Taher; Dany Habr; Nicolas Martin; Gabor Domokos; Maria Domenica Cappellini; Mahidol University; Heinrich Heine Universitat; The Catholic University of Korea; UCL; American University of Beirut; Novartis Pharmaceuticals; Novartis International AG; Universita degli Studi di Milano
1-Feb-2014Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quoAli T. Taher; Khaled M. Musallam; Vip Viprakasit; John B. Porter; Maria Domenica Cappellini; American University of Beirut Medical Center; Mahidol University; UCL; Universita degli Studi di Milano
12-Apr-2011On T2* magnetic resonance and cardiac ironJohn Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J. Anderson; Sofia V. De Noronha; Mary N. Sheppard; John B. Porter; J. Malcolm Walker; John C. Wood; Renzo Galanello; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Michael J. House; Greg Black; David N. Firmin; Timothy G. St. Pierre; Dudley J. Pennell; National Health Service; National Heart and Lung Institute; St George's Hospital, London; UCL; Children's Hospital Los Angeles; Universita degli Studi di Cagliari; E.O. Ospedali Galliera; Azienda Ospedaliera Brotzu; Mahidol University; University of Western Australia
1-Mar-2016Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T. Taher; M. Domenica Cappellini; Yesim Aydinok; John B. Porter; Zeynep Karakas; Vip Viprakasit; Noppadol Siritanaratkul; Antonis Kattamis; Candace Wang; Zewen Zhu; Victor Joaquin; Marie José Uwamahoro; Yong Rong Lai; American University of Beirut Medical Center; Università degli Studi di Milano; Ege University Medical School; UCL; Istanbul Tip Fakultesi; Mahidol University; University of Athens; Novartis Pharmaceuticals; Novartis International AG; Guangxi Medical University
1-Jul-2018A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?Maria Domenica Cappellini; John B. Porter; Vip Viprakasit; Ali T. Taher; American University of Beirut Medical Center; Università degli Studi di Milano; UCL; Faculty of Medicine, Siriraj Hospital, Mahidol University
1-Apr-2011A phase 1 dose-escalation study: Safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHugh Young Rienhoff; Vip Viprakasit; Lay Tay; Paul Harmatz; Elliott Vichinsky; Deborah Chirnomas; Janet L. Kwiatkowski; Amy Tapper; William Kramer; John B. Porter; Ellis J. Neufeld; FerroKin BioSciences, Inc.; Mahidol University; Institute of Medical and Veterinary Science Australia; UCSF Benioff Children's Hospital Oakland; Children's Hospital Boston; The Children's Hospital of Philadelphia; UCL
5-Apr-2012A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J. Neufeld; Renzo Galanello; Vip Viprakasit; Yesim Aydinok; Antonio Piga; Paul Harmatz; Gian Luca Forni; Farrukh T. Shah; Rachael F. Grace; John B. Porter; John C. Wood; Jennifer Peppe; Amber Jones; Hugh Young Rienhoff; Harvard University; Universita degli Studi di Cagliari; Mahidol University; Ege University Medical School; Scienze Cliniche e Biologiche; UCSF Benioff Children's Hospital Oakland; E.O. Ospedali Galliera; Whittington Hospital; UCL; Children's Hospital Los Angeles; FerroKin BioSciences, Inc.
27-Mar-2017Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemiaPaul Kirk; Mary Sheppard; John Paul Carpenter; Lisa Anderson; Taigang He; Tim St Pierre; Renzo Galanello; Gualtiero Catani; John Wood; Suthat Fucharoen; John B. Porter; J. Malcolm Walker; Gian Luca Forni; Dudley J. Pennell; Royal Brompton Hospital; National Heart and Lung Institute; University of Western Australia; Azienda Ospedaliera Brotzu - Microcitemico; Children's Hospital Los Angeles; Mahidol University; UCL; E.O. Ospedali Galliera